Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
X
Share Page
E-mail AlertsE-mail Alerts
IR ContactsIR Contacts

Investor Overview

Webcast ImageWebcast
vTv Therapeutics Inc. at Needham & Co. 16th Annual Healthcare Conference (Live)
04/04/17 at 4:20 p.m. ET
vTv Therapeutics Inc. at Needham & Co. 16th Annual Healthcare Conference
Tuesday, April 4, 2017 4:20 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
vTv Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.
Presentations
DateTitle
03/07/17
Download Documentation Investor Presentation
07/27/16
Download Documentation AAIC 2016 Azeliragon Presentation
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
03/10/17vTv Therapeutics to Present at Two Upcoming Annual Investor Conferences
HIGH POINT, N.C.--(BUSINESS WIRE)--Mar. 10, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, among other therapeutic areas, today announced that company management will present a corporate overview at two upcoming investor conferences. Presentation Details: ROTH Capital Pa... 
Printer Friendly Version
02/27/17vTv Therapeutics Reports 2016 Fourth Quarter and Full Year Financial and Operational Results and Recent Highlights
Completed enrollment of Part A pivotal Phase 3 STEADFAST Study of azeliragon in Alzheimer’s Disease Positive Phase 2 results for Type 2 diabetes therapies, TTP273 and TTP399 HIGH POINT, N.C.--(BUSINESS WIRE)--Feb. 27, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, amo... 
Printer Friendly Version
12/14/16vTv Therapeutics Announces Positive Topline Results from Phase 2 Study of TTP273 in Type 2 Diabetes
Oral small molecule GLP-1 receptor agonist met primary endpoint Company’s second successful Phase 2 diabetes trial in 2016 HIGH POINT, N.C.--(BUSINESS WIRE)--Dec. 14, 2016-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced positive data from its Phase 2 study evaluating TTP273, an oral small molecule GLP-1 receptor (GLP-1R) agonist, for the treatment of Type 2 diabetes. TTP273 demonstrated a statistically significant reduction in Hb... 
Printer Friendly Version
11/16/16New Pre-Clinical Data on a vTv Therapeutics Small Molecule Drug Candidate Against Parkinson’s Disease to be Presented at the Society for Neuroscience 2016 Meeting in San Diego
HIGH POINT, N.C.--(BUSINESS WIRE)--Nov. 16, 2016-- vTv Therapeutics Inc. (vTv, Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered small molecule drug candidates to fill significant unmet medical needs, today announced that Dr. Bobby Thomas, Associate Professor at Medical College of Georgia, Georgia Regents University at Augusta, will present a poster at the Society for Neuro... 
Printer Friendly Version
Webcasts
DateTitle
04/04/17
Download Documentation vTv Therapeutics Inc. at Needham & Co. 16th Annual Healthcare Conference
03/14/17
Download Documentation vTv Therapeutics Inc. at 29th Annual ROTH Conference
Get help downloading or viewing the above file types
Upcoming EventsMore >>
DateTitle
04/04/17 4:20 p.m. ET
vTv Therapeutics Inc. at Needham & Co. 16th Annual Healthcare Conference
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever vTv Therapeutics Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.